Barinthus Biotherapeutics (BRNS) Non-Current Assets (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Non-Current Assets came in at $19.5 million in Q1 2026, down 39.34% YoY from $32.1 million in Q1 2025, and down 4.42% on a QoQ basis from $20.4 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Non-Current Assets (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Non-Current Assets data on file, last reported at $19.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 39.34% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.4 million (down 47.94% YoY) and the FY2025 annual result came in at $20.4 million, down 41.08% from the prior year.
- Non-Current Assets fell to $19.5 million in Q1 2026, from $20.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $61.4 million in Q2 2023 to a low of $19.5 million in Q1 2026.
- A 5-year average of $46.5 million and a median of $55.3 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 1789.55% — and 2025, when it slumped 58.51%.
- Tracing BRNS's Non-Current Assets over 5 years: stood at $57.2 million in 2022, then increased by 0.76% to $57.6 million in 2023, then tumbled by 39.96% to $34.6 million in 2024, then plunged by 41.08% to $20.4 million in 2025, then slipped by 4.42% to $19.5 million in 2026.
- The last three Non-Current Assets figures came in at $19.5 million (Q1 2026), $20.4 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 18.06 Bn |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - | 18.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.62 Mn |
| Mar 31, 2026 | 19.48 Mn |
| Dec 31, 2025 | 20.38 Mn |
| Sep 30, 2025 | 22.42 Mn |
| Jun 30, 2025 | 29.15 Mn |
| Mar 31, 2025 | 32.11 Mn |
| Dec 31, 2024 | 34.59 Mn |
| Sep 30, 2024 | 54.04 Mn |
| Jun 30, 2024 | 54.87 Mn |
| Mar 31, 2024 | 56.35 Mn |
| Dec 31, 2023 | 57.60 Mn |
| Sep 30, 2023 | 58.91 Mn |
| Jun 30, 2023 | 61.35 Mn |
| Mar 31, 2023 | 61.15 Mn |
| Dec 31, 2022 | 57.16 Mn |
| Sep 30, 2022 | 56.86 Mn |
| Jun 30, 2022 | 58.77 Mn |
| Mar 31, 2022 | 55.34 Mn |
| Dec 31, 2021 | 53.95 Mn |
| Sep 30, 2021 | 10.59 Mn |